CRNX Crinetics Pharmaceuticals, Inc.
Healthcare$36.80-0.78%ClosedMarket Cap: $3.88B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.99
P/S
214.74
EV/EBITDA
-7.04
DCF Value
$-6.94
FCF Yield
-10.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
98.9%
Operating Margin
-3020.3%
Net Margin
-2747.2%
ROE
-44.0%
ROA
-35.4%
ROIC
-40.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $10.7M | 98.1% | $-140.4M | $-127.8M | $— | — |
| Q4 null | $6.2M | 100.0% | $-133.7M | $-122.8M | $— | — |
| FY null | $7.7M | 86.0% | $-516.8M | $-465.3M | $— | — |
| Q3 null | $143.0K | 100.0% | $-142.6M | $-130.1M | $— | — |
| Q2 null | $1.0M | 100.0% | $-129.1M | $-115.6M | $— | — |
| Q1 null | $361.0K | 100.0% | $-111.4M | $-96.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-94.7M | $-80.6M | $— | — |
| FY null | $1.0M | 100.0% | $-338.9M | $-298.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-87.8M | $-76.8M | $— | — |
| Q2 null | $399.0K | 100.0% | $-82.8M | $-74.1M | $— | — |
| Q1 null | $640.0K | 100.0% | $-73.5M | $-66.9M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-62.7M | $-60.1M | $-0.89 | — |